?????? ????????????????????????? ?????????????? ?? ????.gene in patients relapsing soon after cure with the BCL2 antagonist venetoclax. 66 Resistance to these brokers has been linked to these mutations in all over 70% of instances, although they are frequently subclonal as well as their particular purpose resulting in resistance has to be establish